Clinical Trial – Treatment for Obstructive Sleep Apnea.

Study to Inform Phase 3 Program Design of AD109 and Advance Program for AD504.
apnea

Potential Treatment for Obstructive Sleep Apneat

Apnimed a clinical-stage pharmaceutical company focused on developing oral pharmacologic treatments to address obstructive sleep apnea (OSA) and related disorders, today announced the dosing of the first patient in the Phase 2b MARIPOSA study of AD109, the company’s lead investigational oral medication for the treatment of OSA.

The study is designed to be informative for the upcoming AD109 Phase 3 program. MARIPOSA also incorporates a sub-study of AD504, a second investigational oral medication being developed by Apnimed as a potential treatment for OSA.

apnea

“There are no approved drugs for the more than 25 million people in the U.S. who have OSA, a common and serious sleep disorder in which breathing is repeatedly interrupted during sleep and that can have life-threatening consequences,” said Larry Miller, M.D., Chief Executive Officer of Apnimed.

“The vast majority of diagnosed patients are prescribed positive airway pressure devices (for example, CPAP) but fewer than half are compliant long-term, leaving them at risk. With the MARIPOSA study underway, we are one step closer to bringing patients a potential new oral treatment option for OSA.”

Share:

More Posts

Send Us A Message